| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Ethyl palmitate targets CHIKV virus as an inhibitor with an EC50 of 0.0068 μM. It also targets inflammatory pathways by reducing levels of TNF-α, IL-6, and NF-κB. The compound increases cytosolic Ca2+ concentration, leading to pancreatic acinar cell injury due to excessive consumption of ethanol. It acts as a lubricant on the skin's surfaces.
|
|---|---|
| ln Vitro |
In vitro, Ethyl palmitate is a CHIKV virus inhibitor with an EC50 of 0.0068 μM. It reduces levels of pro-inflammatory cytokines in cell-based assays. The compound increases cytosolic Ca2+ concentration in pancreatic acinar cells. It is a neutral, lipid-soluble form of palmitic acid. Its antiviral and anti-inflammatory activities have been characterized in various in vitro systems.
|
| ln Vivo |
In vivo, Ethyl palmitate reduces levels of TNF-α, IL-6, and NF-κB in endotoxemic rats, showing anti-inflammatory activity. It is a CHIKV virus inhibitor with potential for antiviral research. The compound acts as a lubricant on the skin's surfaces. Its effects on pancreatic acinar cells due to ethanol consumption have been noted. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for Ethyl palmitate involve measuring CHIKV virus inhibition. Viral replication is assessed in virus-infected cells treated with the compound at varying concentrations. EC50 values are calculated from dose-response curves (EC50 = 0.0068 μM). Anti-inflammatory activity is assessed by measuring TNF-α, IL-6, and NF-κB levels by ELISA. Calcium flux is measured using fluorescent calcium indicators in pancreatic acinar cells. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Ethyl palmitate are conducted in CHIKV-infected cells, immune cells, and pancreatic acinar cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Viral replication is measured by plaque assay or qPCR. Cytokine levels are measured by ELISA. Calcium levels are measured using fluorescent indicators. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Ethyl palmitate in vivo studies are conducted in animal models of viral infection and inflammation. Animals are treated with Ethyl palmitate via oral administration or injection. For CHIKV infection studies, viral load is measured. For anti-inflammatory studies, endotoxemic rat models are used and TNF-α, IL-6, and NF-κB levels are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Ethyl palmitate (MW 284.48 g/mol, C18H36O2) is a fatty acid ethyl ester. It is also known as ethyl hexadecanoate. The compound is a neutral, lipid-soluble form of palmitic acid. It is stable under recommended storage conditions. Ethyl palmitate is used in antiviral, anti-inflammatory, and metabolic research. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Ethyl palmitate is generally well-tolerated in preclinical studies. The compound is a fatty acid ester with established safety profiles. Its antiviral and anti-inflammatory activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Ethyl hexadecanoate is a long-chain fatty acid ethyl ester formed by the condensation of the carboxyl group of palmitic acid with the hydroxyl group of ethanol. It is a plant metabolite. It is both a hexadecanoate and a long-chain fatty acid ethyl ester. Ethyl palmitate has been reported to exist in Bupleurum chinense, Pyrrosia lingua, and other organisms with relevant data. Ethyl hexadecanoate is a metabolite found or produced in Saccharomyces cerevisiae.
Ethyl palmitate (Ethyl hexadecanoate) is a fatty acid ethyl ester and CHIKV virus inhibitor with an EC50 of 0.0068 μM. It reduces TNF-α, IL-6, and NF-κB levels in endotoxemic rats, showing anti-inflammatory activity. The compound increases cytosolic Ca2+ concentration in pancreatic acinar cells. Its molecular formula is C18H36O2 with a molecular weight of 284.48 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C18H36O2
|
|---|---|
| Molecular Weight |
284.4772
|
| Exact Mass |
284.271
|
| CAS # |
628-97-7
|
| Related CAS # |
Ethyl palmitate-d31;1215721-57-5
|
| PubChem CID |
12366
|
| Appearance |
Colorless to light yellow <24°C powder,>26°C liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
342.2±0.0 °C at 760 mmHg
|
| Melting Point |
24-26 °C(lit.)
|
| Flash Point |
149.0±7.5 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.443
|
| LogP |
8.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
20
|
| Complexity |
202
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
XIRNKXNNONJFQO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20-4-2/h3-17H2,1-2H3
|
| Chemical Name |
ethyl hexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~351.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5152 mL | 17.5759 mL | 35.1519 mL | |
| 5 mM | 0.7030 mL | 3.5152 mL | 7.0304 mL | |
| 10 mM | 0.3515 mL | 1.7576 mL | 3.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
